ClinicalTrials.gg

Program

ifebemtinib

Also written as “IN10018”, “BI 853520” and “IN10018 in combination with PLD”.

Its studies are mostly in Ovarian Neoplasms · Neoplasms · Pancreatic Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 5 companies.

Furthest: phase 3, since Aug 29, 202516 company-led studies, 10 open or runningNext primary completion: Mar 24, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InxMed (Shanghai)117 open or runningphase 3since Aug 29, 2025Sep 26, 2019Mar 24, 2027phase 2 · NCT06014528
Boehringer Ingelheim20 open or runningphase 1since Apr 7, 2011Apr 7, 2011none ahead
Hangzhou Hanx Biopharmaceuticals11 open or runningphase 2since Nov 25, 2024Nov 25, 2024Dec 31, 2027phase 2 · NCT06708663
InventisBio11 open or runningphase 2since May 13, 2022May 13, 2022Dec 31, 2027phase 2 · NCT05379946
Shanghai Jeyou Pharmaceutical11 open or runningphase 3since Sep 13, 2026Sep 13, 2026Apr 2029phase 3 · NCT07833202
  • Named in fosun pharma’s own pipeline as IN10018 (FAK), phase 3, as of Sep 21, 2026 (source).

Also a collaborator on its studies: ranok-therapuetics-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 7, 2011First study: phase 1 study in NeoplasmsNew to Boehringer IngelheimBoehringer Ingelheim · NCT01335269 · 96 enrolled · Canada, Netherlands
  2. Jul 12, 2013Phase 1 study in NeoplasmsBoehringer Ingelheim · NCT01905111 · 21 enrolled · Japan, Taiwan
  3. Sep 26, 2019InxMed (Shanghai)'s first study: phase 1 study in MelanomaNew to InxMed (Shanghai)InxMed (Shanghai) · NCT04109456 · 51 enrolled · United States, Australia
  4. Mar 29, 2022Phase 1 study in Stomach NeoplasmsInxMed (Shanghai) · NCT05327231 · 33 enrolled · China
  5. May 13, 2022InventisBio's first study: phase 2 study in Solid TumorNew to InventisBioInventisBio · NCT05379946 · 92 enrolled · China
  6. Sep 15, 2022Phase 2 study in Platinum-resistant Ovarian CancerInxMed (Shanghai) · NCT05551507 · 150 enrolled · China
  7. Mar 28, 20232 phase 2 studiesInxMed (Shanghai) · NCT05827796, NCT05830539
  8. Jul 13, 2023Phase 2 study in Solid TumorInxMed (Shanghai) · NCT05982522
  9. Aug 8, 20232 phase 2 studiesInxMed (Shanghai) · NCT05994131, NCT06014528
  10. Sep 1, 2023Phase 2 study in Small Cell Lung Cancer Extensive StageInxMed (Shanghai) · NCT06030258 · 120 enrolled · China
  11. Nov 25, 2024Hangzhou Hanx Biopharmaceuticals's first study: phase 2 study in Biliary Tract NeoplasmsNew to Hangzhou Hanx BiopharmaceuticalsHangzhou Hanx Biopharmaceuticals · NCT06708663 · 124 planned · China
  12. Aug 29, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungInxMed (Shanghai) · NCT07174908 · 400 planned · China
  13. Feb 13, 2026Phase 2 study in Solid Tumor CancerInxMed (Shanghai) · NCT07441174 · 92 planned · China
  14. Sep 13, 2026Shanghai Jeyou Pharmaceutical's first study: phase 3 study in NSCLCNew to Shanghai Jeyou PharmaceuticalShanghai Jeyou Pharmaceutical · NCT07833202 · 416 planned · China

Ahead

  1. Mar 24, 2027Primary completion: phase 2 study in Ovarian Cancer RecurrentInxMed (Shanghai) · NCT06014528
  2. Dec 31, 2027Primary completion: phase 2 study in Biliary Tract NeoplasmsHangzhou Hanx Biopharmaceuticals · NCT06708663
  3. Dec 31, 2027Primary completion: phase 2 study in Solid TumorInventisBio · NCT05379946
  4. Sep 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungInxMed (Shanghai) · NCT07174908

TargetBeta

PTK2 →read by rule
“An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) ”NCIt, by rule
“Focal adhesion kinase 1 inhibitor”ChEMBL 37, by rule

Other programs on PTK2

ProgramCompanyFurthest phaseStudies
repotrectinibruleBristol-Myers Squibbphase 39

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07833202NSCLC · China3Not yet recruitingShanghai Jeyou PharmaceuticalApr 2029416
NCT07441174Solid Tumor Cancer · China2RecruitingInxMed (Shanghai)Feb 28, 203192
NCT07174908Carcinoma, Non-Small-Cell Lung · China3RecruitingInxMed (Shanghai)Sep 2028400
NCT06708663Biliary Tract Neoplasms · China2RecruitingHangzhou Hanx BiopharmaceuticalsDec 31, 2027124
NCT06030258Small Cell Lung Cancer Extensive Stage · China2Active, not recruitingInxMed (Shanghai)Nov 20, 2025120
NCT06014528Ovarian Cancer Recurrent · China2Active, not recruitingInxMed (Shanghai)Mar 24, 2027168
NCT05994131NSCLC · China2Active, not recruitingInxMed (Shanghai)Sep 20, 2025110
NCT05982522Solid Tumor2WithdrawnInxMed (Shanghai)Dec 31, 20260
NCT05830539Locally Advanced or Metastatic Solid Tumors · China2CompletedInxMed (Shanghai)Aug 31, 202468
NCT05827796Pancreatic Neoplasms · China2Active, not recruitingInxMed (Shanghai)Oct 11, 202570
NCT05551507Platinum-resistant Ovarian Cancer · China2Active, not recruitingInxMed (Shanghai)May 11, 2026150
NCT05379946Solid Tumor · China2Active, not recruitingInventisBioDec 31, 202792
NCT05327231Stomach Neoplasms · China1CompletedInxMed (Shanghai)Dec 3, 202133
NCT04109456Melanoma · United States, Australia1CompletedInxMed (Shanghai)Dec 20, 202451
NCT01905111Neoplasms · Japan, Taiwan1CompletedBoehringer IngelheimAug 201421
NCT01335269Neoplasms · Canada, Netherlands1CompletedBoehringer IngelheimSep 201596

How it is read

Names in the registry

  • “IN10018”, 8 entries
  • “BI 853520”, 2 entries
  • “IN10018 in combination with PLD”, 1 entry
  • “IN10018 in combination with RNK08954”, 1 entry
  • “IN10018 in combination with D-1553”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.